Observational Study of Tirbanibulin Treatment for Actinic Keratosis on the Face Patient and Clinician Outcomes Over 57 Days in U.S. Clinical Practice

What this Trial Is About

This observational study focuses on adults with actinic keratosis AK lesions on the face who are already using tirbanibulin as part of their regular care. The study aims to learn how tirbanibulin affects the overall appearance, look, and texture of the skin over a 57-day period. Researchers want to understand patient and clinician perspectives on skin improvement after treatment. Participants will apply tirbanibulin ointment 1% 3.5 mg in 350 mg once daily for five consecutive days using a single-dose packet. After the treatment, participants will be observed for 57 days to gather patient-reported outcomes and clinical information. The study involves no placebo or comparator groups and focuses on real-world use of the medication. During the study, participants will complete online surveys at the start and at day 57 to assess skin appearance and satisfaction with treatment effects. Researchers will evaluate outcomes including ratings by subjects and clinicians on skin appearance, improvement in skin look and texture, and clinical clearance of AK lesions. The entire study period lasts 57 days, with no additional long-term follow-up mentioned.

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)